Estrogen inhibits mast cell chymase release to prevent pressure overload-induced adverse cardiac remodeling

Hypertension

Volumn 65, Issue 2, 2015, Pages 328-334

  Li, Jianping ^a   Jubair, Shaiban ^a   Janicki, Joseph S ^a  

^a UNIVERSITY OF SOUTH CAROLINA SCHOOL OF MEDICINE   (United States)

Author keywords

cardiac remodeling; chymase; estrogen; mast cell

Indexed keywords

CHYMASE; CHYMOSTATIN; COLLAGEN; ESTRADIOL; ESTROGEN; NEDOCROMIL; TRANSFORMING GROWTH FACTOR BETA1; OLIGOPEPTIDE;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; AORTA CONSTRICTION; ARTICLE; CELL DENSITY; CELL SIZE; CONTROLLED STUDY; DENSITY; ENZYME ACTIVATION; ENZYME BLOOD LEVEL; ENZYME RELEASE; ENZYME SYNTHESIS; ESTROGEN THERAPY; FEMALE; HEART LEFT VENTRICLE FUNCTION; HEART MUSCLE CELL; HEART SIZE; HEART VENTRICLE HYPERTROPHY; HEART VENTRICLE REMODELING; MAST CELL; MAST CELL DEGRANULATION; NONHUMAN; OVARIECTOMY; PRIORITY JOURNAL; PROTEIN CONTENT; RAT; ANIMAL; COMPLICATION; DEGRANULATION; DRUG EFFECTS; ENZYMOLOGY; HEART MUSCLE; HYPERTROPHIC CARDIOMYOPATHY; HYPERTROPHY, LEFT VENTRICULAR; METABOLISM; ORGAN SIZE; PHYSIOLOGY; PREVENTION AND CONTROL; RANDOMIZATION; SECRETION (PROCESS); SPRAGUE DAWLEY RAT; ULTRASTRUCTURE;

ANIMALS; CARDIOMYOPATHY, HYPERTROPHIC; CELL DEGRANULATION; CELL SIZE; CHYMASES; COLLAGEN; ESTRADIOL; ESTROGEN REPLACEMENT THERAPY; FEMALE; HYPERTROPHY, LEFT VENTRICULAR; MAST CELLS; MYOCARDIUM; MYOCYTES, CARDIAC; NEDOCROMIL; OLIGOPEPTIDES; ORGAN SIZE; OVARIECTOMY; RANDOM ALLOCATION; RATS; RATS, SPRAGUE-DAWLEY; TRANSFORMING GROWTH FACTOR BETA1; VENTRICULAR DYSFUNCTION, LEFT; VENTRICULAR REMODELING;

EID: 84921604246     PISSN: 0194911X     EISSN: 15244563     Source Type: Journal    
DOI: 10.1161/HYPERTENSIONAHA.114.04238     Document Type: Article

References (35)

1. Janicki JS, Spinale FG, Levick SP. Gender differences in non-ischemic myocardial remodeling: are they due to estrogen modulation of cardiac mast cells and/or membrane type 1 matrix metalloproteinase. Pflugers Arch. 2013;465:687-697.
2. Gardner JD, Brower GL, Janicki JS. Gender differences in cardiac remodeling secondary to chronic volume overload. J Card Fail. 2002;8:101-107.
3. Brower GL, Gardner JD, Janicki JS. Gender mediated cardiac protection from adverse ventricular remodeling is abolished by ovariectomy. Mol Cell Biochem. 2003;251:89-95.
4. Gardner JD, Brower GL, Voloshenyuk TG, Janicki JS. Cardioprotection in female rats subjected to chronic volume overload: synergistic interaction of estrogen and phytoestrogens. Am J Physiol Heart Circ Physiol. 2008;294:H198-H204.
5. Fliegner D, Schubert C, Penkalla A, Witt H, Kararigas G, Kararigas G, Dworatzek E, Staub E, Martus P, Ruiz Noppinger P, Kintscher U, Gustafsson JA, Regitz-Zagrosek V. Female sex and estrogen receptor-beta attenuate cardiac remodeling and apoptosis in pressure overload. Am J Physiol Regul Integr Comp Physiol. 2010;298:R1597-R1606.
6. Brower GL, Chancey AL, Thanigaraj S, Matsubara BB, Janicki JS. Cause and effect relationship between myocardial mast cell number and matrix metalloproteinase activity. Am J Physiol. 2002;283:H518-H525.
7. Brower GL, Janicki JS. Pharmacologic inhibition of mast cell degranulation prevents left ventricular remodeling induced by chronic volume overload in rats. J Card Fail. 2005;11:548-556.
8. Levick SP, Gardner JD, Holland M, Hauer-Jensen M, Janicki JS, Brower GL. Protection from adverse myocardial remodeling secondary to chronic volume overload in mast cell deficient rats. J Mol Cell Cardiol. 2008;45:56-61.
9. Lu H, Meléndez GC, Levick SP, Janicki JS. Prevention of adverse cardiac remodeling to volume overload in female rats is the result of an estrogen-altered mast cell phenotype. Am J Physiol Heart Circ Physiol. 2012;302:H811-H817.
10. Gardner JD, Murray DB, Voloshenyuk TG, Brower GL, Bradley JM, Janicki JS. Estrogen attenuates chronic volume overload induced structural and functional remodeling in male rat hearts. Am J Physiol Heart Circ Physiol. 2010;298:H497-H504.
11. Chancey AL, Gardner JD, Murray DB, Brower GL, Janicki JS. Modulation of cardiac mast cell-mediated extracellular matrix degradation by estrogen. Am J Physiol Heart Circ Physiol. 2005;289:H316-H321.
12. Urata H, Healy B, Stewart RW, Bumpus FM, Husain A. Angiotensin II-forming pathways in normal and failing heart. Circ Res. 1990;66:883-887.
13. Li P, Chen PM, Wang SW, Chen LY. Time-dependent expression of chymase and angiotensin converting enzyme in the hamster heart under pressure overload. Hypertens Res. 2002;25:757-762.
14. Ihara M, Urata H, Kinoshita A, Suzumiya J, Sasaguri M, Kikuchi M, Ideishi M, Arakawa K. Increased chymase-dependent angiotensin II formation in human atherosclerotic aorta. Hypertension. 1999;33:1399-1405.
15. Ihara M, Urata H, Shirai K, Ideishi M, Hoshino F, Suzumiya J, Kikuchi M, Arakawa K. High cardiac angiotensin-II-forming activity in infarcted and non-infarcted human myocardium. Cardiology. 2000;94:247-253.
16. Urata H, Kinoshita A, Misono KS, Bumpus FM, Husain A. Identification of a highly specific chymase as the major angiotensin II-forming enzyme in the human heart. J Biol Chem. 1990;265:22348-22357.
17. Lindstedt KA, Wang Y, Shiota N, Saarinen J, Hyytiäinen M, Kokkonen JO, Keski-Oja J, Kovanen PT. Activation of paracrine TGF-beta1 signaling upon stimulation and degranulation of rat serosal mast cells: a novel function for chymase. FASEB J. 2001;15:1377-1388.
18. Kofford MW, Schwartz LB, Schechter NM, Yager DR, Diegelmann RF, Graham MF. Cleavage of type I procollagen by human mast cell chymase initiates collagen fibril formation and generates a unique carboxyl-terminal propeptide. J Biol Chem. 1997;272:7127-7131.
19. Kokkonen JO, Kovanen PT. Proteolytic enzymes of mast cell granules degrade low density lipoproteins and promote their granule-mediated uptake by macrophages in vitro. J Biol Chem. 1989;264:10749-10755.
20. Kido H, Nakano A, Okishima N, Wakabayashi H, Kishi F, Nakaya Y, Yoshizumi M, Tamaki T. Human chymase, an enzyme forming novel bioactive 31-amino acid length endothelins. Biol Chem. 1998;379:885-891.
21. Mizutani H, Schechter N, Lazarus G, Black RA, Kupper TS. Rapid and specific conversion of precursor interleukin 1 beta (IL-1 beta) to an active IL-1 species by human mast cell chymase. J Exp Med. 1991;174:821-825.
22. Liu W, Chen J, Xu T, Tian W, Li Y, Zhang Z, Li W. Qiliqiangxin improves cardiac function in spontaneously hypertensive rats through the inhibition of cardiac chymase. Am J Hypertens. 2012;25:250-260.
23. Wang H, Jessup JA, Zhao Z, Da Silva J, Lin M, MacNamara LM, Ahmad S, Chappell MC, Ferrario CM, Groban L. Characterization of the cardiac renin angiotensin system in oophorectomized and estrogen-replete mRen2. Lewis rats. PLoS One. 2013;8:e76992. doi: 10. 1371/journal. pone. 0076992.
24. Gardner JD, Brower GL, Janicki JS. Effects of dietary phytoestrogens on cardiac remodeling secondary to chronic volume overload in female rats. J Appl Physiol (1985). 2005;99:1378-1383.
25. McLarty JL, Meléndez GC, Levick SP, Bennett S, Sabo-Attwood T, Brower GL, Janicki JS. Estrogenic modulation of inflammation-related genes in male rats following volume overload. Physiol Genomics. 2012;44:362-373.
26. McEuen AR, Sharma B, Walls AF. Regulation of the activity of human chymase during storage and release from mast cells: the contributions of inorganic cations, pH, heparin and histamine. Biochim Biophys Acta. 1995;1267:115-121.
27. Wei CC, Hase N, Inoue Y, Bradley EW, Yahiro E, Li M, Naqvi N, Powell PC, Shi K, Takahashi Y, Saku K, Urata H, Dell'italia LJ, Husain A. Mast cell chymase limits the cardiac efficacy of Ang I-converting enzyme inhibitor therapy in rodents. J Clin Invest. 2010;120:1229-1239.
28. Ahmad S, Simmons T, Varagic J, Moniwa N, Chappell MC, Ferrario CM. Chymase-dependent generation of angiotensin II from angiotensin-(1-12) in human atrial tissue. PLoS One. 2011;6:e28501. doi: 10. 1371/journal. pone. 0028501.
29. Singh VP, Le B, Bhat VB, Baker KM, Kumar R. High-glucose-induced regulation of intracellular ANG II synthesis and nuclear redistribution in cardiac myocytes. Am J Physiol Heart Circ Physiol. 2007;293:H939-H948.
30. Jin D, Takai S, Yamada M, Sakaguchi M, Kamoshita K, Ishida K, Sukenaga Y, Miyazaki M. Impact of chymase inhibitor on cardiac function and survival after myocardial infarction. Cardiovasc Res. 2003;60:413-420.
31. Takai S, Jin D, Sakaguchi M, Katayama S, Muramatsu M, Sakaguchi M, Matsumura E, Kim S, Miyazaki M. A novel chymase inhibitor, 4-[1-([bis-(4-methyl-phenyl)-methyl]-carbamoyl)3-(2-ethoxy-benzyl)-4-oxo-azetidine-2-yloxy]-benzoic acid (BCEAB), suppressed cardiac fibrosis in cardiomyopathic hamsters. J Pharmacol Exp Ther. 2003;305:17-23.
32. Matsumoto T, Wada A, Tsutamoto T, Ohnishi M, Isono T, Kinoshita M. Chymase inhibition prevents cardiac fibrosis and improves diastolic dysfunction in the progression of heart failure. Circulation. 2003;107:2555-2558.
33. Dobaczewski M, Chen W, Frangogiannis NG. Transforming growth factor (TGF)-signaling in cardiac remodeling. J Mol Cell Cardiol. 2011;51:600-606.
34. Levick SP, Meléndez GC, Plante E, McLarty JL, Brower GL, Janicki JS. Cardiac mast cells: the centrepiece in adverse myocardial remodelling. Cardiovasc Res. 2011;89:12-19.
35. Dubey RK, Gillespie DG, Jackson EK, Keller PJ. 17Beta-estradiol, its metabolites, and progesterone inhibit cardiac fibroblast growth. Hypertension. 1998;31(1 Pt 2):522-528.